Literature DB >> 17945286

mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype.

F Christoph1, S Hinz, C Kempkensteffen, M Schostak, M Schrader, K Miller.   

Abstract

PURPOSE: We determined the relation between promoter methylation and mRNA expression of the p53 target genes APAF-1 and DAPK-1 in 55 consecutive tumor and corresponding normal tissue samples.
MATERIALS AND METHODS: Tissue was taken from nonmetastatic clear cell renal cell carcinoma at a median followup of 75 months. Quantitative methylation specific real-time polymerase chain reaction and quantitative real-time reverse transcriptase-polymerase chain reaction were used.
RESULTS: The mRNA expression levels of APAF-1 and DAPK-1 were significantly higher in tumor vs nontumor tissue from the same kidney (p = 0.003 and 0.0001, respectively). Expression levels of the 2 genes did not correlate with tumor stage but they were significantly lower in high grade (G3) tumors (p = 0.018 and 0.05, respectively). In patients with positive lymph node staging mRNA expression of APAF-1 and DAPK-1 was significantly lower. On matched pair analysis of tumor tissue the methylation level of the APAF-1 gene correlated inversely with the mRNA expression level (p = 0.02). In tumor and normal kidney tissue from patients with lesions 4 cm or greater mRNA expression levels of DAPK-1 were significantly lower in those who later had metastatic disease (p = 0.04 and 0.02, respectively).
CONCLUSIONS: These data demonstrate decreased tumor suppressor gene expression in more aggressive subtypes of clear cell renal cell carcinoma. The lower mRNA level of the DAPK-1 gene in tumor and normal tissue from patients with an unfavorable clinical outcome suggests the organ specific loss of tumor suppressor gene expression, predisposing to metastatic tumor disease and shorter overall survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945286     DOI: 10.1016/j.juro.2007.07.116

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 2.  The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.

Authors:  Qiwei Yang; Aymara Mas; Michael P Diamond; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2015-04-28       Impact factor: 3.060

3.  Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population.

Authors:  Shiekh Tanveer Ahmad; Wani Arjumand; Amlesh Seth; Ashish Kumar Saini; Sarwat Sultana
Journal:  Tumour Biol       Date:  2011-09-16

4.  Effects of 5-Aza-CdR on the proliferation of human breast cancer cell line MCF-7 and on the expression of Apaf-1 gene.

Authors:  Huihua Xiong; Hong Qiu; Liang Zhuang; Hua Xiong; Rui Jiang; Yuan Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-08-07

5.  Aberrant Methylation-Mediated Suppression of APAF1 in Myelodysplastic Syndrome.

Authors:  Farhad Zaker; Nahid Nasiri; Naser Amirizadeh; Seyed Mohsen Razavi; Marjan Yaghmaie; Ladan Teimoori-Toolabi; Ali Maleki; Masoumeh Bakhshayesh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-04-01

6.  Inhibition of miR-34a-5p can rescue disruption of the p53-DAPK axis to suppress progression of clear cell renal cell carcinoma.

Authors:  Zhi-Fei Jing; Jian-Bin Bi; Zeliang Li; Xiankui Liu; Jun Li; Yuyan Zhu; Xiao-Tong Zhang; Zhe Zhang; Zhenhua Li; Chui-Ze Kong
Journal:  Mol Oncol       Date:  2019-08-24       Impact factor: 6.603

Review 7.  Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway.

Authors:  Ramy F Youssef; Nicholas G Cost; Oussama M Darwish; Vitaly Margulis
Journal:  Arab J Urol       Date:  2012-04-09

8.  Aberrant Methylation of APAF-1 Gene in Acute Myeloid Leukemia Patients.

Authors:  Shahrbano Rostami; Fatemeh Nadali; Reza Alibakhshi; Farhad Zaker; Nahid Nasiri; Mehrdad Payandeh; Bahram Chahardouli; Ali Maleki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.